Vidofludimus

Summary

Vidofludimus (CHEMBL197194) is a phase-3 clinical-stage small molecule targeting DHODH and NR4A2; indicated across 7 conditions including relapsing-remitting multiple sclerosis and multiple sclerosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 2 (DHODH, NR4A2)
• Indications: 7 conditions
• Clinical trials: 10
• Chemistry: 355.4 Da · C20H18FNO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL197194
Name	Vidofludimus
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9820008
Molecular formula	C20H18FNO4
Molecular weight	355.4
InChIKey	XPRDUGXOWVXZLL-UHFFFAOYSA-N

SMILES: COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F

IUPAC name: 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid

Also known as: 4SC-101, Imu-838, IMU-838, NSC-717824, SC-12267, SC12267, Vidofludimus, SID174007069, VIDOFLUDIMUS, IMU838

Parent form; salt/anhydrous children: CHEMBL5405308

Patent coverage: 282 distinct patent families (808 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 697 (86%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
DHODH	dihydroorotate dehydrogenase (quinone)	Inhibition	7.32	33.9%	Q02127
NR4A2	Nuclear receptor related 1	Activation	6.4	0.6%	P43354

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Nuclear receptor subfamily 4immunitygroup A member 1, Nuclear receptor subfamily 4 group A member 3, Dihydroorotate dehydrogenase (quinone), mitochondrial, Bile acid receptor, Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7, Nuclear receptor subfamily 4 group A member 2.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 15 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DHODH	6.87	IC50	134	nM	CHEMBL_ACT_1602455
DHODH	6.87	IC50	134	nM	CHEMBL_ACT_1665584
DHODH	6.87	IC50	134	nM	CHEMBL_ACT_24776167
NR4A2	6.52	EC50	300	nM	CHEMBL_ACT_25540425
NR4A2	6.4	EC50	400	nM	CHEMBL_ACT_25540414
NR4A2	6.4	EC50	400	nM	CHEMBL_ACT_25703018
NR1H4	6.35	EC50	450	nM	CHEMBL_ACT_25009531
DHODH	6.21	IC50	610	nM	CHEMBL_ACT_25703068
NR4A2	6.16	Kd	700	nM	CHEMBL_ACT_25540435
NR4A2	6.16	Kd	700	nM	CHEMBL_ACT_25703139
DHODH	5.56	EC50	2754	nM	CHEMBL_ACT_22457186
DHODH	5.55	EC50	2800	nM	CHEMBL_ACT_22457184
NR4A3	5.54	EC50	2900	nM	CHEMBL_ACT_25703119
NR4A1	5.51	EC50	3100	nM	CHEMBL_ACT_25703097
JMJD7	5.14	IC50	7160	nM	CHEMBL_ACT_23213691

Target pathways

Aggregated over 2 target gene(s): DHODH, NR4A2.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Nuclear Receptor transcription pathway	1	NR4A2
SUMOylation of intracellular receptors	1	NR4A2
Pyrimidine biosynthesis	1	DHODH

Dominant GO biological processes

GO term	Targets
‘de novo’ pyrimidine nucleobase biosynthetic process	1
UDP biosynthetic process	1
pyrimidine ribonucleotide biosynthetic process	1
‘de novo’ UMP biosynthetic process	1
pyrimidine nucleotide biosynthetic process	1
UMP biosynthetic process	1
negative regulation of transcription by RNA polymerase II	1
response to hypoxia	1
neuron migration	1
response to amphetamine	1
DNA-templated transcription	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
adult locomotory behavior	1
post-embryonic development	1

Indications & clinical

Indications

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
relapsing-remitting multiple sclerosis	3	MONDO:0005314	EFO:0003929
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
ulcerative colitis	2	MONDO:0005101	EFO:0000729
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
inflammatory bowel disease	2	MONDO:0005265	EFO:0003767
sclerosing cholangitis	2	MONDO:0018646	EFO:0004268
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05134441	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT04379271	PHASE2/PHASE3	COMPLETED	A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
NCT03846219	PHASE2	ACTIVE_NOT_RECRUITING	MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
NCT00820365	PHASE2	COMPLETED	SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
NCT01010581	PHASE2	COMPLETED	SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis
NCT03341962	PHASE2	TERMINATED	Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
NCT03722576	PHASE2	COMPLETED	Vidofludimus Calcium for Primary Sclerosing Cholangitis
NCT04516915	PHASE2	COMPLETED	IMU-838 and Oseltamivir in the Treatment of COVID-19
NCT05054140	PHASE2	UNKNOWN	Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

24 molecules share ≥1 primary target. Top 24 by shared-target count:

Molecule	Source	Status	Shared targets
ALPROSTADIL	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
BEXAROTENE	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
CHLOROQUINE	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
MECLOFENAMIC ACID	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
OXAPROZIN	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
PITAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
SIMVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	NR4A2
AMODIAQUINE	ChEMBL	Phase 4 (approved)	NR4A2
ATOVAQUONE	ChEMBL	Phase 4 (approved)	DHODH
FLUVASTATIN	ChEMBL	Phase 4 (approved)	NR4A2
LEFLUNOMIDE	ChEMBL	Phase 4 (approved)	DHODH
PARECOXIB	ChEMBL	Phase 4 (approved)	NR4A2
TERIFLUNOMIDE	ChEMBL	Phase 4 (approved)	DHODH
ASLAN-003	ChEMBL	Phase 2	DHODH
BREQUINAR	ChEMBL	Phase 2	DHODH
CLONIXIN	ChEMBL	Phase 2	DHODH
FLUNIXIN	ChEMBL	Phase 2	DHODH
LINOLEIC ACID	ChEMBL	Phase 2	NR4A2
NIFLUMIC ACID	ChEMBL	Phase 2	DHODH
OLEIC ACID	ChEMBL	Phase 2	NR4A2
OXYCINCHOPHEN	ChEMBL	Phase 2	DHODH
PIPERINE	ChEMBL	Phase 2	DHODH
TECASTEMIZOLE	ChEMBL	Phase 2	NR4A2
Doconexent	PubChem	Approved	NR4A2